Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Diagnostic test company Alere Inc. can’t get a second bite at the same apple ( Alere, Inc. v. Rembrandt Diagnostics LP , P.T.A.B., No. IPR 2017-01130, petition denied 9/28/17 ).
The Patent Trial and Appeal Board rejected Alere’s request to review the validity of certain claims in Rembrandt Inc.'s drug test kit patent, finding it didn’t show why it couldn’t have raised the challenges in an earlier challenge it filed on the same patent.
The PTAB declined Alere’s invitation to review for a second time U.S. Patent No. 6,548,019, which claims a kit, including test cups and test strips, that can be used to collect and quickly screen urine samples for illicit drugs or other substances. The Sept. 28 decision to deny a second review of the Rembrandt patent reflects the board’s concern about the high potential for abuse of the patent review process posed by multiple petition filings by the same petitioner against the same patent.
In this case, Alere and its subsidiary and co-petitioner Innovacon had already brought a challenge to the ’019 patent before the PTAB in 2016. The board instituted review of some of the patent claims in February but not on the claims Alere pressed in its second request. Determining it shouldn’t institute a second review of the patent, the board applied a seven-factor test it set out Sept. 6 in Gen. Plastic Indus Co. v. Canon Kabushiki Kaisha.
Some of these factors include:
The board also noted a Nov. 7 final hearing was already scheduled on the first petition and, even if it had agreed to hear the second petition, it would have been too late to join the two cases.
But the board didn’t need to go through an exhaustive analysis to deny the request, APJ Christopher L. Crumbley said in a separate concurring opinion.
“The instant Petition contains no justification for Petitioner’s subsequent challenge, or explanation why the grounds presented were not brought at the time of the first Petition,” Crumbley said. This alone, he said, was enough for the board to deny review.
Bloomberg BNA contacted the parties for comment on the board’s decision but no one was available to respond.
Alere, based in Waltham, Mass., is set to be acquired by Abbott Laboratories if the companies receive final Federal Trade Commission approval. The FTC tentatively approved the deal Sept. 28 on the condition Abbott sell two point-of-care medical testing businesses it owns: a blood gas testing system and a cardiac marker system.
Meanwhile, the Justice Department closed an investigation into the company’s sales, sales practices, and dealings with certain third parties—primarily occurring at previously acquired foreign subsidiaries, without taking any action against Alere, the company said in a Sept. 29 statement.
Rembrandt is suing Alere and Innovacon in California district court, alleging Alere’s sales of competing test cups infringes the ’019 patent and an additional patent covering dip testing devices.
APJ Brian P. Murphy also joined the majority opinion.
Goodwin Procter LLP represented Alere and Innovacon. Innovacon, based in San Diego, is a wholly owned subsidiary of Alere.
Knobbe Martens Olson & Bear LLP represented Rembrandt, based in Bala Cynwyd, Pa.
To contact the reporter on this story: Dana A. Elfin in Washington at email@example.com
To contact the editor responsible for this story: Brian Broderick at firstname.lastname@example.org
The PTAB's decision is at http://src.bna.com/s1L.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)